Inclusion Criteria:  Histologically confirmed diagnosis of RCC Patients being treated with standard of Programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 immune-checkpoint inhibitor-containing standard of care regimen including patients who are about to start treatment or have been on treatment for a maximum of 4 weeks prior to signing consent Metastatic Measurable disease, as defined by RECIST 1.1 Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 with a life expectancy ≥ six months Physically able to enroll in the exercise program as determined by the treating medical oncologist and after review by Physical medicine and rehabilitation physicians at Johns Hopkins Adequate bone marrow reserve and organ function measured within 28 days prior to administration of study treatment with the following key parameters:  Hematological:  Absolute neutrophil count ≥ 1.5 × 109/L Platelets ≥ 100 × 109/L Hemoglobin≥ 9.0 g/dL  Renal:  Serum Creatinine ≤ 1.5 x the upper limit of normal (ULN) or Calculated Creatinine clearance ≥ 30mL/min  Hepatic:  Total bilirubin ≤ 1.5 x ULN (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled) Serum Aspartate aminotransferase (AST) and serum Alanine aminotransferase (ALT) ≤ 2.5 x ULN (For patients with documented liver metastases AST and/or ALT ≤ 5 x ULN)  Exclusion Criteria:  The presence of bone metastasis in the spine, pelvis, and lower limbs Currently physically active or moderately active as determined by Leisure Score Index of Godin Leisure-Time Exercise Questionnaire (GSLTPAQ) History of underlying cardiovascular, respiratory, musculoskeletal disease or joint problems that preclude moderate physical activity Known underlying uncontrolled brain metastatic lesions requires steroids therapy and/or radiotherapy Major surgery within four weeks prior to enrollment. Radiotherapy for RCC 28 days prior to week 1 day 1